<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030550</url>
  </required_header>
  <id_info>
    <org_study_id>DS 01-16</org_study_id>
    <secondary_id>RPCI-DS-0116</secondary_id>
    <secondary_id>CELGENE-T-MDS-001</secondary_id>
    <secondary_id>NCI-G01-2044</secondary_id>
    <nct_id>NCT00030550</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic&#xD;
      syndrome.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating&#xD;
      anemia in patients who have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of thalidomide for the treatment of anemia in patients with&#xD;
           myelodysplastic syndromes.&#xD;
&#xD;
        -  Determine whether this drug reduces the frequency of leukemia transformation and&#xD;
           decreases bone marrow blast percentage in these patients.&#xD;
&#xD;
        -  Determine the effect of this drug on neutrophil and platelet production and the number&#xD;
           of episodes of febrile neutropenia in these patients.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to International Prognostic Scoring System score (low and&#xD;
      intermediate-1 vs intermediate-2 and high) and transfusion dependence (yes vs no). Patients&#xD;
      are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral thalidomide once daily on weeks 1-24.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily on weeks 1-24. In both arms, patients&#xD;
           who have not progressed to leukemia after 24 weeks of therapy may receive open-label&#xD;
           thalidomide for an additional 24 weeks in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 220 patients (110 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of myelodysplastic syndromes (MDS) of at least 12 weeks duration&#xD;
&#xD;
               -  Refractory anemia (RA)&#xD;
&#xD;
               -  RA with ringed sideroblasts&#xD;
&#xD;
               -  RA with excess blasts&#xD;
&#xD;
               -  Chronic myelomonocytic&#xD;
&#xD;
          -  No therapy-related MDS&#xD;
&#xD;
          -  No myelosclerosis or myelofibrosis occupying more than 30% of marrow space (or&#xD;
             assessed as grade 3+ or greater)&#xD;
&#xD;
          -  No transformation to acute myeloid leukemia&#xD;
&#xD;
          -  No more than 20% blasts in bone marrow&#xD;
&#xD;
          -  No more than 5% blasts in peripheral blood&#xD;
&#xD;
          -  Patients with an erythropoietin level 100 mU/mL or less must have failed epoetin alfa&#xD;
             treatment (i.e., at least 30,000 units of epoetin alfa weekly for at least 6 weeks)&#xD;
&#xD;
          -  Transfusion-dependent (received at least 2 units of packed RBCs or whole blood within&#xD;
             the past 8 weeks) OR&#xD;
&#xD;
          -  Transfusion-independent (no packed RBC or whole blood transfusions within the past 8&#xD;
             weeks with 2 hemoglobin levels (at least 7 days apart) less than 11 g/dL)&#xD;
&#xD;
          -  No iron deficiency (e.g., absent bone marrow iron store)&#xD;
&#xD;
               -  If marrow aspirate is not evaluable, transferrin saturation must be at least 20%&#xD;
                  and ferritin at least 50 ng/mL&#xD;
&#xD;
          -  No uncorrected B12 or folate deficiency&#xD;
&#xD;
          -  No other contributing causes of anemia (e.g., autoimmune or hereditary hemolytic&#xD;
             disorders or gastrointestinal blood loss)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count at least 500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No clinically significant, symptomatic, unstable cardiovascular disease unrelated to&#xD;
             MDS&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No clinically significant, symptomatic, unstable pulmonary disease unrelated to MDS&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No clinically significant, symptomatic, unstable neurologic disease unrelated to MDS&#xD;
&#xD;
          -  No history of epilepsy&#xD;
&#xD;
          -  No sustained neurologic deficit (e.g., stroke)&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use at least 1 highly effective and 1 additional effective&#xD;
             method of contraception for 4 weeks prior to, during, and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No clinically significant, symptomatic, unstable endocrine, gastrointestinal, or&#xD;
             genitourinary disease unrelated to MDS&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No life-threatening or active infection requiring parenteral antibiotics&#xD;
&#xD;
          -  No other serious concurrent illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 7 days since prior hematopoietic growth factors (e.g., epoetin alfa,&#xD;
             filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-3)&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
          -  No prior agents intended to inhibit vascular endothelial growth factor or tumor&#xD;
             necrosis factor alfa (e.g., etanercept or infliximab)&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy that may be active against MDS&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  More than 30 days since prior androgens&#xD;
&#xD;
          -  No requirement for ongoing therapy with systemic corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 30 days since prior treatment for MDS except RBC transfusion or epoetin alfa&#xD;
&#xD;
          -  More than 30 days since prior participation in another experimental clinical trial&#xD;
&#xD;
          -  More than 30 days since prior experimental drugs&#xD;
&#xD;
          -  No other concurrent investigational agents or treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L. Slack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

